Can Acute Myeloid Leukemia be treated via the EVI1 gene?
- Researcher: Professor Ruud Delwel
- Institution: Erasmus University Rotterdam
- Award Amount: £193,399 for 3 years from June 2012
- Cancer Type: Leukaemia
Acute Myeloid Leukemia, or AML, is a cancer that affects some of our white blood cells. A gene called EVI1 appears to play a role in the development of AML, as well as some other cancers, including ovarian cancer. By genetically removing EVI1 from cells in the lab it was possible to kill AML tumour cells that normally have the EVI1 gene. It is not possible to cut the EVI1 gene out of the cancer cells in a person with AML, but it might be possible to design treatments that stop the EVI1 gene from working. Professor Delwel wants to use his new Worldwide Cancer Research grant to stop EVI1 from working in AML by preventing the gene from interacting with other proteins. His research group have previously identified some of these proteins. They now want to learn more about how these interactions work, whether they can be stopped, and whether these interactions have an effect on other genes that might play a role in cancer.
The Research That Is Happening Right Now
Explore current projects to see how far-reaching our research is from a global perspective.
See the difference our research projects make.